Studies Library
The published research our coverage is built on, catalogued with study-type metadata so readers can weigh evidence quality — a phase 3 trial and an in-vitro report are not the same kind of fact.
| Study | Type | Compounds | Date |
|---|---|---|---|
| Oral delivery of GLP-1 receptor agonists: absorption-enhancer platforms Reports improved oral bioavailability for GLP-1-class peptides using next-generation absorption enhancers. | Preclinical (primate) | ||
| Tirzepatide versus semaglutide in adults with obesity (SURMOUNT-5) Direct comparison favoring tirzepatide on weight endpoints at matched treatment intent. | Head-to-head randomized trial | ||
| Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT) 20% reduction in major adverse cardiovascular events, extending GLP-1 evidence beyond weight and glycemia. | Cardiovascular outcomes trial | ||
| Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial Mean weight reduction of up to 24.2% at 48 weeks at the highest dose, the largest reported in an obesity trial at publication. | Randomized controlled trial (Phase 2) | ||
| Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) Up to 20.9% mean weight reduction at 72 weeks; established dual-incretin agonism at phase 3 scale. | Randomized controlled trial (Phase 3) | ||
| Once-weekly semaglutide in adults with overweight or obesity (STEP 1) 14.9% mean weight reduction at 68 weeks versus 2.4% with placebo. | Randomized controlled trial (Phase 3) | ||
| Thymosin beta-4 ophthalmic solution for dry eye (phase 3 program) The furthest-advanced human application of TB4 biology; results mixed across endpoints. | Randomized controlled trial (Phase 3) | ||
| Bremelanotide for hypoactive sexual desire disorder (RECONNECT) Paired phase 3 trials supporting FDA approval of bremelanotide (Vyleesi). | Randomized controlled trial (Phase 3) | ||
| BPC 157 and the vascular system: modulation of angiogenesis Reviews VEGF-mediated angiogenic mechanisms proposed for BPC-157 across injury models. | Mechanistic review | ||
| The human tripeptide GHK-Cu in skin remodeling and regeneration Comprehensive review of GHK-Cu dermatological evidence including controlled cosmetic comparisons. | Review | ||
| MOTS-c is an exercise-induced mitochondrial-encoded regulator of metabolism Foundational paper establishing MOTS-c as a metabolically active mitochondrial-derived peptide. | Animal + human observational | ||
| Stable gastric pentadecapeptide BPC 157 in tendon-to-bone healing Improved tendon-to-bone healing outcomes in a rat transection model; representative of the compound’s preclinical base. | Animal model | ||
| Selank anxiolytic activity in generalized anxiety disorder Basis of Russian approval; methodology details unavailable in translated literature. | Controlled clinical trial | ||
| Tesamorelin for visceral adiposity in HIV-associated lipodystrophy Pivotal trial demonstrating selective visceral-fat reduction; basis of FDA approval. | Randomized controlled trial (Phase 3) | ||
| AOD9604 in obese adults: a randomized dose-ranging study Failed to meet weight-loss endpoints; development discontinued. | Randomized controlled trial (Phase 2b) | ||
| Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults Demonstrated multi-day GH/IGF-1 elevation from the DAC-modified GHRH analog. | Randomized controlled trial (Phase 1) | ||
| Semax in acute ischemic stroke: multicenter clinical experience Russian clinical evidence base for Semax; not independently replicated in Western trials. | Clinical series | ||
| Thymosin beta-4 promotes cardiomyocyte survival after coronary ligation Landmark cardiac-repair finding that anchored interest in thymosin beta-4 biology. | Animal model | ||
| Epithalon and telomerase activity in human somatic cells Reported telomerase activation in vitro; central to the compound’s longevity claims and largely unreplicated independently. | In vitro | ||
| Ipamorelin, the first selective growth hormone secretagogue Characterized selective GH release without significant cortisol/prolactin elevation. | Preclinical characterization |